Zydus Worldwide DMCC to Acquire Assertio Holdings in All-Cash $166.4 Million Tender Offer

Curium US Holdings to Acquire Lantheus Holdings in Up to $8.0B Deal

August 3, 2026

Healthcare Services

Curium US Holdings LLC has entered into a definitive agreement to acquire all outstanding shares of Lantheus Holdings, Inc. for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights (CVRs) potentially paying up to an additional $12.00 per share tied to commercial milestones through 2030. The transaction is valued at up to approximately $8.0 billion and is expected to close in the first half of 2027, subject to customary approvals and regulatory clearances.

Garda Therapeutics to Acquire Assertio Holdings for $125.1 Million

April 8, 2026

Healthcare Services

Assertio Holdings agreed to be acquired by Garda Therapeutics in an all-cash tender offer valued at approximately $125.1 million, plus a contingent value right (CVR). The deal includes a sale of Assertio’s non-Rolvedon assets to Cosette Pharmaceuticals for $35 million upfront, and the combined transactions are expected to close in the second quarter of 2026 (subject to customary conditions).

Zydus Lifesciences Acquires Agenus' U.S. Biologics Manufacturing Facilities and Launches Zylidac Bio LLC

January 16, 2026

Biotechnology

Zydus Lifesciences Limited has completed purchase agreements with Agenus Inc. to acquire Agenus' biologics manufacturing facilities and operations in Emeryville and Berkeley, California, and has established a U.S. CDMO subsidiary, Zylidac Bio LLC, to operate the assets. The deal includes exclusive manufacturing arrangements for Agenus' Phase 3 immuno-oncology candidates (botensilimab and balstilimab), exclusive commercialization rights for those assets in India and Sri Lanka, and an equity investment in Agenus via Zynext Ventures; regulatory approvals including CFIUS clearance were secured.

Zydus Lifesciences Acquires 85.6% of Amplitude Surgical and Launches Mandatory Tender Offer

March 11, 2025

Medical Devices

Zydus Lifesciences Limited entered into exclusive negotiations to buy a controlling 85.6% stake in Amplitude Surgical, valuing the block at €256.8 million (€6.25 per share), from PAI Partners and certain minority shareholders. After regulatory conditions were fulfilled, the 85.6% stake was completed, and Zydus will file (and then conduct) a simplified mandatory tender offer for the remaining shares at the same €6.25 price, followed by a squeeze-out to delist.

Assertio Holdings Acquires Spectrum Pharmaceuticals

April 25, 2023

Pharmaceuticals

Assertio Holdings, Inc. agreed to acquire all outstanding shares of Spectrum Pharmaceuticals, Inc. in an all-stock transaction with contingent value rights (CVRs), expected to close in Q3 2023. The deal combines Assertio's digital, non-personal commercial capabilities with Spectrum's in-person commercial team and ROLVEDON (eflapegrastim-xnst) to accelerate the product's launch and broaden the combined company's pharmaceutical portfolio.

Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics

August 31, 2020

Biotechnology

Ionis Pharmaceuticals agreed to acquire the approximately 24% of Akcea Therapeutics it does not already own for $18.15 per share in cash, implying a fully diluted transaction value of about $500 million. The deal will be executed via a tender offer followed by a second-step merger, and Ionis expects to complete the transaction in Q4 2020 to consolidate Akcea's pipeline, commercial products and cash while realizing cost synergies.